Shots:

• Alvotech has filed a federal lawsuit to end the monopoly on AbbVie’s Humira for taking several improper steps to inflate its patent portfolio includes multiple patents on the same invention and obtain patents through inequitable conduct
• Alvotech develops AVT02 as a biosimilar of Humira for chronic pain with equal in strength to Humira’s latest formulation and develops AVT02 as an interchangeable product and expects the results from its ongoing interchangeability study in Q2’21
• The biosimilars are available across EU and in Japan- Canada- and Australia and expect to save US taxpayers and the overall healthcare system of $8-10B annually

  Ref: BUSINESS WIRE | Image: Alvotech